| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pierre-Michel Llorca, Jean-Pierre Kahn, Véronique Moreau-Mallet, Philippe Bouhours, The French StoRMi Investigators Grou. Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable. International journal of psychiatry in clinical practice. vol 10. issue 4. 2014-06-20. PMID:24941147. |
to investigate efficacy and tolerability of risperidone long-acting injectable (rlai) in french patients with schizophrenia or other psychotic disorders, who were all switching from previous treatment with oral atypical antipsychotics. |
2014-06-20 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Marek Jarem. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International journal of psychiatry in clinical practice. vol 8. issue 3. 2014-06-20. PMID:24941204. |
long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: an international multicenter study. |
2014-06-20 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Marek Jarem. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International journal of psychiatry in clinical practice. vol 8. issue 3. 2014-06-20. PMID:24941204. |
objective the aim of this open multicenter international study was an assessment of the efficacy and tolerability of risperidone administered for 12 months in patients with early schizophrenia. |
2014-06-20 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Marek Jarem. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International journal of psychiatry in clinical practice. vol 8. issue 3. 2014-06-20. PMID:24941204. |
conclusion the results suggest that, in a substantial proportion of patients with early schizophrenia, risperidone can be successfully used for initiation of pharmacological treatment of schizophrenia and then be continued on the long-term basis. |
2014-06-20 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
the aims of this 13-week study were to examine the efficacy and safety of amisulpride, and effects on cognitive function in patients with schizophrenia after they switched from risperidone. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
twenty-three patients with schizophrenia whose antipsychotic was switched from risperidone to amisulpride were recruited. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
switching antipsychotic from risperidone to amisulpride in schizophrenia might have significantly improved not only the efficacy, but also various domains of cognitive function. |
2014-06-17 |
2023-08-13 |
Not clear |
| Phil Lee, Chul Eung Kim, Chang Yoon Kim, Wei-Wen Lin, Hussain Habil, Yulia Dyachkova, Margaret Mcbride, Martin Dossenbac. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931661. |
long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (ic-soho) study. |
2014-06-17 |
2023-08-13 |
Not clear |
| Phil Lee, Chul Eung Kim, Chang Yoon Kim, Wei-Wen Lin, Hussain Habil, Yulia Dyachkova, Margaret Mcbride, Martin Dossenbac. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931661. |
to compare the effectiveness of olanzapine, risperidone, quetiapine, or haloperidol monotherapy in patients with schizophrenia who were treated in routine clinical practice settings for a period of 2 years. |
2014-06-17 |
2023-08-13 |
Not clear |
| Phil Lee, Chul Eung Kim, Chang Yoon Kim, Wei-Wen Lin, Hussain Habil, Yulia Dyachkova, Margaret Mcbride, Martin Dossenbac. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931661. |
outpatients with schizophrenia who entered this 3-year, prospective, observational study were classified according to their initially prescribed antipsychotic monotherapy: olanzapine (n=3222), risperidone (n=1116), quetiapine (n=189), or haloperidol (n=256). |
2014-06-17 |
2023-08-13 |
Not clear |
| A Hal. Sertindole: a clinical efficacy profile. International journal of psychiatry in clinical practice. vol 6. issue 1. 2014-06-17. PMID:24931885. |
it is at least as efficacious as haloperidol and risperidone in treating the overall and positive symptoms of schizophrenia and has been shown to have advantages over these two drugs with respect to the treatment of the negative symptoms of schizophrenia. |
2014-06-17 |
2023-08-13 |
Not clear |
| J K Borkowsk. The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. International journal of psychiatry in clinical practice. vol 5. issue 4. 2014-06-14. PMID:24921692. |
the effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. |
2014-06-14 |
2023-08-13 |
Not clear |
| Beata Konarzewska, Beata Galińska-Skok, Napoleon Waszkiewicz, Joanna Łazarczyk-Kirejczyk, Aleksandra Malus, Katarzyna Simonienko, Agata Szul. Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. Neuro endocrinology letters. vol 35. issue 1. 2014-06-12. PMID:24625910. |
association between serum testosterone levels, body mass index (bmi) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. |
2014-06-12 |
2023-08-12 |
Not clear |
| Beata Konarzewska, Beata Galińska-Skok, Napoleon Waszkiewicz, Joanna Łazarczyk-Kirejczyk, Aleksandra Malus, Katarzyna Simonienko, Agata Szul. Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone. Neuro endocrinology letters. vol 35. issue 1. 2014-06-12. PMID:24625910. |
the main purpose of the present study was to examine the correlations between testosterone, estradiol bmi, and insulin in male patients diagnosed with schizophrenia and treated with olanzapine or risperidone. |
2014-06-12 |
2023-08-12 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Bong-Jin Hahm, Kyung Sue Hong, Jin-Sang Yoon, Young-Hoon Kim, Won-Myong Bahk, Sang-Yeol Lee, Yanghyun Lee, In-Won Chung, Chan-Hyung Ki. Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics. International journal of psychiatry in clinical practice. vol 13. issue 3. 2014-06-12. PMID:24916820. |
the aim of this non-randomized, single-arm, multi-center, 9-month extension study was to evaluate the maintained efficacy and tolerability of long-acting risperidone injection when we switched to it from previous oral antipsychotics in symptomatically stable patients with schizophrenia or other psychotic disorders. |
2014-06-12 |
2023-08-13 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Bong-Jin Hahm, Kyung Sue Hong, Jin-Sang Yoon, Young-Hoon Kim, Won-Myong Bahk, Sang-Yeol Lee, Yanghyun Lee, In-Won Chung, Chan-Hyung Ki. Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics. International journal of psychiatry in clinical practice. vol 13. issue 3. 2014-06-12. PMID:24916820. |
switching to long-acting risperidone injection from oral antipsychotics was a safe and well-tolerated strategy for maintaining clinical stability in symptomatically stable patients with schizophrenia. |
2014-06-12 |
2023-08-13 |
Not clear |
| Birgit Spill, Silvia Konoppa, Werner Kissling, Katja Maino, Thomas Messer, Stephan Here. Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. International journal of psychiatry in clinical practice. vol 14. issue 1. 2014-06-12. PMID:24917233. |
the aim of the present 18-month retrospective study was to assess the association between a continuous long-term treatment with risperidone long-acting injectable (rlai) of at least 12 months and in-patient care of patients suffering of schizophrenia or schizoaffective disorder. |
2014-06-12 |
2023-08-13 |
Not clear |
| Chi-Un Pae, Alberto Chiesa, Ashwin A Patkar, Alessandro Serrett. No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone. International journal of psychiatry in clinical practice. vol 14. issue 3. 2014-06-12. PMID:24917325. |
the aim of the present study is to investigate whether slc6a3 40 base vntr polymorphism could modulate response to risperidone in a sample of korean schizophrenia subjects. |
2014-06-12 |
2023-08-13 |
human |
| Chi-Un Pae, Alberto Chiesa, Ashwin A Patkar, Alessandro Serrett. No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone. International journal of psychiatry in clinical practice. vol 14. issue 3. 2014-06-12. PMID:24917325. |
one hundred and forty-two schizophrenia inpatients were treated with a flexible dose of risperidone. |
2014-06-12 |
2023-08-13 |
human |